Integra takes cranial technology to "$80 million" US sector:
This article was originally published in Clinica
Integra LifeSciences Holdings plans to start selling this month in the US its KraniOS cranial closure system for closing cranial bone flaps. The product consists of low-profile titanium implants for reduced palpability and screws designed with a head that allows for stable insertion, said the Plainsboro, New Jersey firm, which will market the system through its domestic Integra NeuroSciences sales force. The screws also have the strength to minimise stripping while maintaining a low profile.
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.